| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C9H14N2O |
| Molar mass | 166.224 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
ABT-418 is a drug developed byAbbott, that hasnootropic,neuroprotective andanxiolytic effects,[1][2][3][4][5] and has been researched for treatment of bothAlzheimer's disease[6] andADHD.[7][8][9] It acts as anagonist at neuralnicotinic acetylcholine receptors,subtype-selective binding with highaffinity to theα4β2,α7/5-HT3, and α2β2nicotinic acetylcholine receptors but notα3β4 receptors[10][11][12] ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principallynausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.[13]
This article about ananxiolytic is astub. You can help Wikipedia byadding missing information. |